¿Evita la antibioterapia biopsias de próstata en pacientes con valores elevados de PSA? / Does Antibiotherapy Prevent Unnecessary Prostate Biopsies in Patients With High PSA Values?

Introducción: Investigamos si la antibioterapia tiene algún papel en el PSA total (tPSA), PSA libre (fPSA) y fPSA/tPSA en pacientes con PSA superior a 2,5ng/ml. También si tiene alguna relación con la tasa de diagnóstico de cáncer de próstata. Material y métodos: Un total de 108 pacientes mayores de 50 años con síntomas del tracto urinario inferior y PSA>2,5ng/ml fueron incluidos en este estudio. Se dio antibioterapia a todos los casos durante tres semanas. Luego se tomó biopsias con guía ultrasonográfica a todos los pacientes. Antes y después de la antibioterapia se les aplicó los cuestionarios International Prostate Sypmtom Score (IPSS) y National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) y se comparó los valores de tPSA, fPSA y fPSA/tPSA en sangre. Resultados: Las variaciones de tPSA, fPSA y fPSA/tPSA antes y después de la antibioterapia no mostraron diferencias estadísticamente significativas (p>0,05). Cuando excluimos el adenocarcinoma de próstata se hallaron diferencias estadísticamente significativas en las puntuaciones del IPSS y NIH-CPSI en todos los casos. Conclusiones: La administración de antibioterapia a pacientes con niveles de PSA superiores a los valores de corte no produjo un cambio significativo en la decisión de realizar biopsias de próstata con aguja. Se debería considerar realizar biopsias de próstata sin antibioterapia previa en los pacientes con PSA elevado cuando no exista una sospecha de prostatitis (AU)

Introduction: We investigated if antibiotherapy has any role on total PSA (tPSA), free PSA (fPSA) and fPSA/tPSA ratio in patients with tPSA higher than 2.5 ng/ml. We also analyzed if it has any relation with prostate cancer diagnosis rate. Material and Methods: A total 108 patients older than 50 years of age with lower urinary system sypmtoms and tPSA >2.5ng/ml were included in this study. Antibiotherapy was given to all the cases for three weeks. After that, transrectal ultrasound-guided prostate biopsies were taken from all the patients. Before and after antibiotherapy, "The International Prostate Symptom Score" (IPSS) and "National Institutes of Health Chronic Prostatitis Symptom Index" (NIH-CPSI) questinories are performed and serum tPSA, fPSA and fPSA/tPSA values were obtained. Results: TPSA, fPSA and fPSA/tPSA ratio alterations prior to and after antibiotherapy did not show any statistically significant difference (p>0.05). When prostate adenocarcinoma was excluded, an statistically significant decrease was found in IPSS and NIH-CPSI scores for all cases. Conclusions: Antibiotherapy given to patients with PSA levels higher than threshold value has not led to significant change in prostate needle biopsy decision. Prostate biopsy should be considered without trying antibiotherapy in patients with high PSA values if a suspicion of prostatitis does not exist (AU)

[Does antibiotherapy prevent unnecessary prostate biopsies in patients with high PSA values?]. / ¿Evita la antibioterapia biopsias de próstata en pacientes con valores elevados de PSA?

INTRODUCTION: We investigated if antibiotherapy has any role on total PSA (tPSA), free PSA (fPSA) and fPSA/tPSA ratio in patients with tPSA higher than 2.5ng/ml. We also analyzed if it has any relation with prostate cancer diagnosis rate. MATERIAL AND METHODS: A total 108 patients older than 50 years of age with lower urinary system sypmtoms and tPSA >2.5ng/ml were included in this study. Antibiotherapy was given to all the cases for three weeks. After that, transrectal ultrasound-guided prostate biopsies were taken from all the patients. Before and after antibiotherapy, "The International Prostate Symptom Score" (IPSS) and "National Institutes of Health Chronic Prostatitis Symptom Index" (NIH-CPSI) questinories are performed and serum tPSA, fPSA and fPSA/tPSA values were obtained. RESULTS: TPSA, fPSA and fPSA/tPSA ratio alterations prior to and after antibiotherapy did not show any statistically significant difference (p>0.05). When prostate adenocarcinoma was excluded, an statistically significant decrease was found in IPSS and NIH-CPSI scores for all cases. CONCLUSIONS: Antibiotherapy given to patients with PSA levels higher than threshold value has not led to significant change in prostate needle biopsy decision. Prostate biopsy should be considered without trying antibiotherapy in patients with high PSA values if a suspicion of prostatitis does not exist.

[Major urologic surgical procedures in locally advanced colorectal cancers]. / Procedimientos quirúrgicos urológicos mayores en el cáncer colorrectal localmente avanzado.

OBJECTIVE: To evaluate the outcomes of major urological procedures performed in patients with locally advanced colorectal cancer. MATERIAL AND METHODS: Data of 37 patients with locally advanced colorectal cancer who underwent major urological surgical procedures along with simultaneous cancer surgery between the years of 2005 and 2010 were retrospectively evaluated. RESULTS: The mean age was 58.3 years. Male/Female ratio was 2.7. 59% of the patients were primary, and 41% were recurrent cases of colorectal cancer. Bladder, ureters, urethra, kidneys and prostate were found as invaded in 19, 9, 5, 2 and 2 cases, respectively. The following single or combined procedures were performed; partial (n=11) or total (n=8; 2 combined with urethrocutaneostomy, 6 with ileal-conduit) cystectomy, urethroplasty (n=5), nephroureterectomy (n=2), radical nephrectomy (n=1), partial nephrectomy (n=1), ureteroneocystostomy (n=7), Boari's flap (n=4), transureteroureterostomy (n=3). Prolonged drainage was the most common surgical complication (27%). Urethrocutaneous fistula and total urinary incontinence were encountered in 1 and 1 patient, respectively. The incidence of hydronephrosis and elevated creatinine were 38% (preoperative 27%; postoperative 11%) and 24% (11% preoperative; 13% postoperative), respectively. Two deaths occurred in the first month of operations. Mean duration of follow up was 18(6-28) months for surviving 13 patients. Overall survival in 24 cases resulting in death was 21(1-42) months. CONCLUSIONS: Since the most important eventual effects of locally advanced colorectal cancer are on the kidneys from the urological point of view; the aim of an urologist, as a member of surgical team, should be preserving renal function in addition to helping complete removal of the tumor.

[Treatment of urogenital fistula in women]. / Tratamiento de la fístula urogenital en la mujer.

INTRODUCTION AND OBJECTIVES: We aimed to assess the results of the genitourinary fistula cases intervened in our center in a ten year period. PATIENTS AND METHODS: We evaluated the clinical data regarding genitourinary fistula from the medical records of 42 female patients who underwent surgery for this condition between May 2001 and June 2010. Age, previous medical history, diagnostic tools used, operative data and clinical outcomes of the patients were evaluated retrospectively. RESULTS: The mean age of patients was 51 years. Of 42 patients, 28 had vesicovaginal, 11 had ureterovaginal, and 3 had vesicouterine fistulas. Etiology of vesicovaginal fistula was surgical trauma in 71,5% and obstetric trauma in 28,5% of the patients. O'Connor technique was performed as a single procedure in 12 vesicovaginal fistula cases, and ureteroneocystostomy was added in 3. Transvesical repair was performed in 9, and transvaginal repair in 3 of the patients. All of 11 patients with ureterovaginal fistula were of iatrogenic origin; ureteroneocystostomy was performed in 6, and Boari flap was performed in 5 of these patients. Three vesicouterine fistulas were repaired primarily. Success rates in vesicovaginal, ureterovaginal and vesicouterine fistulas were 96, 100 and 100 percent, respectively. CONCLUSION: In experienced hands and according with the related basic surgical principles, operative treatment in genitourinary fistula represents an effective modality with high success rate.

Efficacy of testosterone gel in the treatment of erectile dysfunction in hypogonadal hemodialysis patients: a pilot study.

End-stage renal disease (ESRD) affects sexual function. The etiology of sexual dysfunction in ESRD is multifactorial and hypogonadism is not uncommon. In a cohort of 96 men with ESRD, scores on International Index of Erectile Function (IIEF) correlated with bioavailable testosterone (T; P<0.01). We further evaluated the effects of administration of T on ED in hypogonadal men on hemodialysis. Nine men with ED and hypogonadism (baseline bioavailable T <3.82 nmol l(-1)), received 5 g T-gel (1% (10 mg g(-1)) per day treatment for 6 months. The IIEF and frequency of sexual intercourse per week were used to assess treatment efficacy. T administration significantly increased serum T levels to the normal range, and was associated with statistically significant improvements of the scores of the IIEF domains (erectile function from 7.6+/-8.0 to 12.8+/-7.8; intercourse satisfaction from 3.4+/-4.5 to 4.8+/-3.1; orgasmic function from 4.8+/-3.1 to 3.4+/-2.9; sexual desire from 3.4+/-2.9 to 4.4+/-0.6; overall sexual satisfaction from 2.6+/-1.3 to 3.8+/-1.0). But scores of the IIEF did not normalize. Frequency of weekly sexual intercourse increased from 0.4+/-0.4 to 1.1+/-0.8 (P<0.05) after 6 months. There were no adverse effects. We conclude that restoring T levels to normal in men with ESRD improved scores on the IIEF and frequency of weekly sexual intercourse.